bioRxivImmunology
Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustion
S. De Munter, J. Buhl, L. De Cock, A. Van Parys, W. Daneels, E. Pascal, L. Deseins, J. Ingels, G. Goetgeluk, L. Billiet, M. Pille, N. Vandamme, J. Van Dorpe, F. Offner, E. Depla, J. Tavernier, T. Kerre, J. Drost, B. Vandekerckhove
Abstract
CD70 is an attractive target for chimeric antigen receptor (CAR) T cell therapy as treatment for both solid and liquid malignancies. However, functionality of CD70-specific CARs is only modest. Here, we optimized a CD70-specific VHH based CAR (nanoCAR). We evaluated the nanoCARs in clinically relevant models in vitro, using co-cultures of CD70-specific nanoCAR T cells with malignant rhabdoid tumor organoids, and in vivo by using a diffuse large B cell lymphoma (DLBCL) patient-derived xenograft (PDX) model. Whereas the nanoCAR T cells were highly efficient in organoid co-cultures, they showed only modest efficacy in the PDX model. Knocking out CD70 expression by the nanoCAR T cells resulted in dramatically enhanced functionality in the PDX model, suggesting that endogenous CD70 interaction with the nanoCAR induces exhaustion. Through single-cell transcriptomics, we obtained evidence that CD70KO CD70-specific nanoCAR T cells are protected from antigen induced exhaustion. Our data shows that CARs targeted to endogenous T cell antigens, negatively affect CAR T cell functionality by inducing an exhausted state which can be overcome by knocking out the specific target, in this case CD70.
- organism: human
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell-cell communication
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies
Adila Izgutdina, Tasfia Rashid, … Arun P. Wiita·Journal for ImmunoTherapy of CancerPeer-reviewed·Dec 1, 2025
- In vivo programming of stem-like CAR T cells by lymphatic-selective lipid nanoparticle enables durable anti-tumour efficacy in orthotopic model
- The Identification of IL-4 as a Regulator of Chimeric Antigen Receptor T Cell Exhaustion
C. M. Stewart, E. L. Siegler, … S. S. Kenderian·bioRxiv·Sep 28, 2023
- Acquisition of an immunosuppressive microenvironment after CAR-T therapy drives T-cell dysfunction and resistance
Marianna Ponzo, Lorenzo Drufuca, … Chiara Francesca Magnani·Journal for ImmunoTherapy of CancerPeer-reviewed·Oct 1, 2025
- c-Jun Overexpressing CAR-T Cells are Exhaustion-Resistant and Mediate Enhanced Antitumor Activity
R. C. Lynn, E. W. Weber, … C. L. Mackall·bioRxiv·May 29, 2019
- Repeated stimulation or tonic-signaling chimeric antigen receptors drive regulatory T cell exhaustion
C. Lamarche, G. Novakovsky, … M. K. Levings·bioRxiv·Jun 27, 2020